BioCentury
ARTICLE | Company News

Laboratorios Farmaceuticos Rovi, Novavax deal

February 15, 2010 8:00 AM UTC

Novavax terminated its 2009 deal to license its recombinant virus-like particle (VLP) vaccine technology to Laboratorios Farmaceuticos to develop seasonal and pandemic influenza vaccines for the Spani...